Leading provider of toxicology and bioanalytical contract services, Agilex Biolabs, says it has expanded its capacity to provide services to the biotechnology, pharmaceutical and animal health industry with the opening of its new in-vivo testing facility in Brisbane.
The company that has supported the industry for 25 years said it has expanded its capacity by 500 per cent with the addition of a new purpose-built Good Laboratory Practice (GLP) toxicology facility. Agilex said this expansion makes it the largest GLP Toxicology service provider in the region.
"We are thrilled to add more talented people to the team, shorten lead times further, be more agile, and enhance our superior level of safety assessment service to the global biotech, pharmaceutical and animal health industries," said chief commercial officer Holly Stefl.
The new custom-built facility has over 10,000 square feet of laboratory space. It is equipped with state-of-the-art individually ventilated, environmentally monitored, high-tech enabled systems scheduled for accreditation by Australia's National Association of Testing Authorities as a Biosafety Level 2 facility.
"The already installed modern industry systems and standards ensure that our sponsors will continue to receive the best in the industry with forethought, and results that can be backed by the Agilex brand to the level of accepted regulatory requirements and evaluations of innovative therapeutics and vaccines," said the company.
Agilex completed multiple SARS-CoV-2 fast-track programs on behalf of its sponsors in the last two years, including mRNA, adenovirus, and molecular clamp stabilized protein subunit vaccines. It is the only toxicology study provider in Australia to accommodate CAR-T therapy programs with immunocompromised models.
